Wet Age-Related Macular Degeneration

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Theodore Leng, MD, FACS, discusses results of the FARETINA-AMD study investigating faricimab for wet age-related macular degeneration.

SEATTLE — In this Healio Video Perspective from OIS Retina, Nancy Lurker discusses an update on the ongoing phase 2 DAVIO 2 trial, as well as the demographic data in the completed phase 1 DAVIO 1 trial and the DAVIO 2 trial

AsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the development of its lead clinical candidate, AXT107, for the treatment of neovascular retinal diseases, according to a press release.

Kodiak Sciences is discontinuing development of tarcocimab tedromer, citing results of the GLEAM and GLIMMER phase 3 studies in diabetic macular edema, according to a press release.

Bispecific agents appear promising in broadening the treatment landscape in wet age-related macular degeneration and diabetic macular edema, but much remains to be learned about this emerging class of agents.

Healio spoke with Yasha S. Modi, MD to discuss the current treatment landscape for AMD, treatment options, how AMD can affect a patient's lifestyle, and what clinicians should consider in their awareness of AMD.

Healio spoke with Yasha S. Modi, MD to discuss the current treatment landscape for AMD, treatment options, how AMD can affect a patient's lifestyle, and what clinicians should consider in their awareness of AMD.

Healio spoke with Yasha S. Modi, MD to discuss the current treatment landscape for AMD, treatment options, how AMD can affect a patient's lifestyle, and what clinicians should consider in their awareness of AMD.

Healio spoke with Yasha S. Modi, MD to discuss the current treatment landscape for AMD, treatment options, how AMD can affect a patient's lifestyle, and what clinicians should consider in their awareness of AMD.

Healio spoke with Yasha S. Modi, MD to discuss the current treatment landscape for AMD, treatment options, how AMD can affect a patient's lifestyle, and what clinicians should consider in their awareness of AMD.